CN102939290B - 2,3-二氢-1h-茚-1-基-2,7-二氮杂螺[3.5]壬烷衍生物及其作为生长激素释放肽受体的拮抗剂或反向激动剂的用途 - Google Patents
2,3-二氢-1h-茚-1-基-2,7-二氮杂螺[3.5]壬烷衍生物及其作为生长激素释放肽受体的拮抗剂或反向激动剂的用途 Download PDFInfo
- Publication number
- CN102939290B CN102939290B CN201180014627.7A CN201180014627A CN102939290B CN 102939290 B CN102939290 B CN 102939290B CN 201180014627 A CN201180014627 A CN 201180014627A CN 102939290 B CN102939290 B CN 102939290B
- Authority
- CN
- China
- Prior art keywords
- dihydro
- diazaspiro
- inden
- nonane
- acetyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 CC(C*C(CC1)C(NN2)=C1N=C2I)(CC1)CC*1C(C*)=O Chemical compound CC(C*C(CC1)C(NN2)=C1N=C2I)(CC1)CC*1C(C*)=O 0.000 description 2
- CESURFROKLKXQI-GOSISDBHSA-N C(C1(C2)CCNCC1)N2[C@H](CCc1c2)c1ccc2-c1ncccn1 Chemical compound C(C1(C2)CCNCC1)N2[C@H](CCc1c2)c1ccc2-c1ncccn1 CESURFROKLKXQI-GOSISDBHSA-N 0.000 description 1
- CKYFZKMPRIVFKW-UHFFFAOYSA-N CC1(C)OB(c(cc2CC3)ccc2C3=O)OC1(C)C Chemical compound CC1(C)OB(c(cc2CC3)ccc2C3=O)OC1(C)C CKYFZKMPRIVFKW-UHFFFAOYSA-N 0.000 description 1
- IUQZUQHAPZPOPD-JOCHJYFZSA-N COC(N1CCC(C2)(CN2[C@H](CCc2c3)c2ccc3-c(nc2)ccc2C#N)CC1)=O Chemical compound COC(N1CCC(C2)(CN2[C@H](CCc2c3)c2ccc3-c(nc2)ccc2C#N)CC1)=O IUQZUQHAPZPOPD-JOCHJYFZSA-N 0.000 description 1
- UHUCZYJVWVZKAH-AREMUKBSSA-N COc1ccc(CC(N2CCC(C3)(CN3[C@H](CCc3c4)c3ccc4-c3ncccn3)CC2)=O)cc1 Chemical compound COc1ccc(CC(N2CCC(C3)(CN3[C@H](CCc3c4)c3ccc4-c3ncccn3)CC2)=O)cc1 UHUCZYJVWVZKAH-AREMUKBSSA-N 0.000 description 1
- NATXGJPPVHDYCP-HHHXNRCGSA-N Cc1cc(-c2ccc([C@@H](CC3)N(C4)CC4(CC4)CCN4C(Cc(cc4)ncc4OC)=O)c3c2)ncn1 Chemical compound Cc1cc(-c2ccc([C@@H](CC3)N(C4)CC4(CC4)CCN4C(Cc(cc4)ncc4OC)=O)c3c2)ncn1 NATXGJPPVHDYCP-HHHXNRCGSA-N 0.000 description 1
- VHFDGOBPNBOUNA-HXUWFJFHSA-N Cc1nccc(-c2ccc([C@@H](CC3)N(C4)CC44CCNCC4)c3c2)n1 Chemical compound Cc1nccc(-c2ccc([C@@H](CC3)N(C4)CC44CCNCC4)c3c2)n1 VHFDGOBPNBOUNA-HXUWFJFHSA-N 0.000 description 1
- IEUKCNPRRGOGDG-SECBINFHSA-N N[C@H](CC1)c(cc2)c1cc2Br Chemical compound N[C@H](CC1)c(cc2)c1cc2Br IEUKCNPRRGOGDG-SECBINFHSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4747—Quinolines; Isoquinolines spiro-condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31552210P | 2010-03-19 | 2010-03-19 | |
| US61/315,522 | 2010-03-19 | ||
| US201161444401P | 2011-02-18 | 2011-02-18 | |
| US61/444,401 | 2011-02-18 | ||
| PCT/IB2011/051035 WO2011114271A1 (en) | 2010-03-19 | 2011-03-11 | 2,3 dihydro-1h-inden-1-yl- 2,7-diazaspiro [3.6] nonane derivatives and their use as antagonists or inverse agonists of the ghrelin receptor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102939290A CN102939290A (zh) | 2013-02-20 |
| CN102939290B true CN102939290B (zh) | 2015-09-16 |
Family
ID=44647714
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201180014627.7A Expired - Fee Related CN102939290B (zh) | 2010-03-19 | 2011-03-11 | 2,3-二氢-1h-茚-1-基-2,7-二氮杂螺[3.5]壬烷衍生物及其作为生长激素释放肽受体的拮抗剂或反向激动剂的用途 |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US8609680B2 (enExample) |
| EP (1) | EP2547679B1 (enExample) |
| JP (1) | JP5496409B2 (enExample) |
| KR (1) | KR101455917B1 (enExample) |
| CN (1) | CN102939290B (enExample) |
| AR (1) | AR080688A1 (enExample) |
| AU (1) | AU2011228699B2 (enExample) |
| BR (1) | BR112012023664B1 (enExample) |
| CA (1) | CA2792234C (enExample) |
| CY (1) | CY1118721T1 (enExample) |
| DK (1) | DK2547679T3 (enExample) |
| ES (1) | ES2557895T3 (enExample) |
| HR (1) | HRP20151232T1 (enExample) |
| HU (1) | HUE025774T2 (enExample) |
| IL (1) | IL221952A (enExample) |
| ME (1) | ME02330B (enExample) |
| MX (1) | MX2012010772A (enExample) |
| PH (1) | PH12012501800A1 (enExample) |
| PL (1) | PL2547679T3 (enExample) |
| PT (1) | PT2547679E (enExample) |
| RS (1) | RS54383B1 (enExample) |
| RU (1) | RU2524341C2 (enExample) |
| SG (1) | SG183812A1 (enExample) |
| SI (1) | SI2547679T1 (enExample) |
| TW (1) | TWI410423B (enExample) |
| WO (1) | WO2011114271A1 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2854856B1 (en) * | 2012-06-04 | 2019-01-23 | Pfizer Inc | Use of ghrelin receptor inverse agonists or antagonists for treating sleep disorders |
| TWI633087B (zh) * | 2012-06-13 | 2018-08-21 | 赫孚孟拉羅股份公司 | 新穎二氮雜螺環烷及氮雜螺環烷 |
| HRP20191937T1 (hr) | 2012-09-25 | 2020-01-10 | F. Hoffmann - La Roche Ag | Derivati heksahidropirolo [3,4-c]pirola i srodni spojevi kao inhibitori autotaksina (atx) i kao inhibitori proizvodnje lizofosfatidne kiseline (lpa) za liječenje npr. bubrežnih bolesti |
| AR095079A1 (es) | 2013-03-12 | 2015-09-16 | Hoffmann La Roche | Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo |
| US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
| US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
| LT3074400T (lt) | 2013-11-26 | 2018-02-12 | F. Hoffmann-La Roche Ag | Oktahidro-ciklobuta [1,2-c;3,4-c`]dipirolo dariniai kaip autotaksino inhibitoriai |
| JP6574438B2 (ja) * | 2014-03-17 | 2019-09-11 | リマインド エヌヴイＲｅｍｙｎｄ Ｎｖ | ２，７−ジアザスピロ［３．５］ノナン化合物 |
| PE20161223A1 (es) | 2014-03-26 | 2016-11-12 | Hoffmann La Roche | Compuestos condensados de [1,4]diazepina como inhibidores de la produccion de autotaxina (atx) y acido lisofosfatidico (lpa) |
| EA037928B1 (ru) | 2014-03-26 | 2021-06-08 | Ф. Хоффманн-Ля Рош Аг | Бициклические соединения в качестве ингибиторов продукции аутотаксина (atx) и лизофосфатидиловой кислоты (lpa) |
| CN106749002A (zh) * | 2015-02-12 | 2017-05-31 | 佛山市赛维斯医药科技有限公司 | 一种含硝基喹啉结构的葡萄糖激酶活化剂及其用途 |
| MA41898A (fr) | 2015-04-10 | 2018-02-13 | Hoffmann La Roche | Dérivés de quinazolinone bicyclique |
| MX377277B (es) | 2015-09-04 | 2025-03-07 | Hoffmann La Roche | Derivados de fenoximetilo. |
| EP3353178B1 (en) | 2015-09-24 | 2021-07-14 | F. Hoffmann-La Roche AG | Bicyclic compounds as dual atx/ca inhibitors |
| AU2016328365B2 (en) | 2015-09-24 | 2020-04-23 | F. Hoffmann-La Roche Ag | New bicyclic compounds as dual ATX/CA inhibitors |
| CA2991615A1 (en) | 2015-09-24 | 2017-03-30 | F. Hoffmann-La Roche Ag | Bicyclic compounds as atx inhibitors |
| AU2016328535A1 (en) | 2015-09-24 | 2017-11-09 | F. Hoffmann-La Roche Ag | Bicyclic compounds as ATX inhibitors |
| KR102882225B1 (ko) | 2017-02-21 | 2025-11-07 | 엘지전자 주식회사 | 냉장고 |
| BR112019019017A2 (pt) | 2017-03-16 | 2020-04-14 | Hoffmann La Roche | compostos heterocíclicos de utilidade como inibidores duplos de atx/ca |
| JP7090099B2 (ja) | 2017-03-16 | 2022-06-23 | エフ．ホフマン－ラ ロシュ アーゲー | Ａｔｘインヒビターとしての新規二環式化合物 |
| AU2018306619B2 (en) * | 2017-07-28 | 2022-06-02 | Chemocentryx, Inc. | Immunomodulator compounds |
| CN108588215A (zh) * | 2018-05-03 | 2018-09-28 | 成都中创清科医学检验所有限公司 | 一种用于检测家族性高胆固醇血症易感性相关的snp位点的引物及其检测方法 |
| CN109970631A (zh) * | 2019-03-26 | 2019-07-05 | 上海吉奉生物科技有限公司 | 一种5-碘-2-吡啶乙酸的合成方法 |
| UY38630A (es) | 2019-04-03 | 2020-10-30 | Vertex Pharma | Agentes moduladores del regulador de la conductancia transmembrana de la fibrosis quística |
| CN111777559B (zh) * | 2019-04-23 | 2021-11-09 | 苏州大学 | 基于端炔制备多取代吡唑的方法 |
| CN110172062B (zh) * | 2019-06-21 | 2022-01-07 | 南京药石科技股份有限公司 | 一种单氟代螺环化合物的合成方法及其中间体 |
| EP4013760A1 (en) * | 2019-08-14 | 2022-06-22 | Vertex Pharmaceuticals Incorporated | Crystalline forms of cftr modulators |
| US20240246959A1 (en) | 2020-11-27 | 2024-07-25 | Shenzhen Salubris Pharmaceuticals Co., Ltd. | Benzimidazole derivative and preparation method therefor and medical use thereof |
| AU2021397294A1 (en) | 2020-12-10 | 2023-07-06 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
| KR20220001745U (ko) | 2021-01-06 | 2022-07-13 | 성보라 | 자동차시트 후면 보호용 보조커버 |
| US12303604B1 (en) | 2024-10-16 | 2025-05-20 | Currax Pharmaceuticals Llc | Pharmaceutical formulations comprising naltrexone and/or bupropion |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1898239A (zh) * | 2003-10-23 | 2007-01-17 | 阿斯利康(瑞典)有限公司 | 新的二氮杂螺烷及其在治疗ccr8介导的疾病中的用途 |
| WO2007007069A1 (en) * | 2005-07-07 | 2007-01-18 | Vernalis (R & D) Limited | Azacyclic compounds as inhibitors of sensory neurone specific sodium channels |
| CN101541795A (zh) * | 2006-09-15 | 2009-09-23 | 先灵公司 | 用于治疗疼痛、糖尿病和脂类代谢紊乱的螺-稠合氮杂环丁烷衍生物 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3595B (en) | 1993-01-21 | 1995-12-27 | Schering Corp | Spirocycloalkyl-substituted azetidinones useful as hypocholesterolemic agents |
| EA200300944A1 (ru) | 2001-02-28 | 2004-04-29 | Мерк Энд Ко., Инк. | Ацилированные пиперидиновые производные в качестве агонистов рецептора-4 меланокортина |
| CA2460340C (en) | 2001-09-21 | 2011-02-15 | Schering Corporation | Methods and therapeutic combinations for the treatment of xanthoma using sterol absorption inhibitors |
| HRP20040716A2 (en) | 2002-02-27 | 2005-02-28 | Pfizer Products Inc. | Acc inhibitors |
| HRP20090471T1 (hr) | 2004-05-12 | 2009-10-31 | Pfizer Products Inc. | Derivati prolina i njihova upotreba kao inhibitori dipeptidil-peptidaze iv |
| JP4069159B2 (ja) | 2004-05-25 | 2008-04-02 | ファイザー・プロダクツ・インク | テトラアザベンゾ［ｅ］アズレン誘導体及びそれらのアナログ |
| PA8660701A1 (es) | 2005-02-04 | 2006-09-22 | Pfizer Prod Inc | Agonistas de pyy y sus usos |
| WO2007058322A1 (ja) | 2005-11-18 | 2007-05-24 | Ono Pharmaceutical Co., Ltd. | 塩基性基を含有する化合物およびその用途 |
| AU2006331770A1 (en) | 2005-12-21 | 2007-07-05 | Schering Corporation | Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and H3 receptor antagonist/inverse agonist |
| EP2463283B1 (en) | 2006-04-20 | 2014-06-11 | Pfizer Products Inc. | Fused phenyl Amido heterocyclic compounds for the prevention and treatment of glucokinase-mediated diseases |
| EP2091534A1 (en) * | 2006-09-15 | 2009-08-26 | Schering Corporation | Azetidinone derivatives and methods of use thereof |
| CN101541809A (zh) | 2006-11-29 | 2009-09-23 | 辉瑞产品公司 | 螺环酮乙酰基-CoA羧化酶抑制剂 |
| US20090036425A1 (en) | 2007-08-02 | 2009-02-05 | Pfizer Inc | Substituted bicyclolactam compounds |
| ES2545231T3 (es) | 2008-05-28 | 2015-09-09 | Pfizer Inc. | Inhibidores de pirazoloespirocetona acetil-CoA carboxilasa |
| EP2297164A1 (en) | 2008-05-28 | 2011-03-23 | Pfizer Inc. | Pyrazolospiroketone acetyl-coa carboxylase inhibitors |
| CA2727914A1 (en) * | 2008-06-19 | 2009-12-23 | Banyu Pharmaceutical Co., Ltd. | Spirodiamine-diaryl ketoxime derivative technical field |
| JP2011529483A (ja) | 2008-07-29 | 2011-12-08 | ファイザー・インク | フッ素化ヘテロアリール |
| MX2011002166A (es) | 2008-08-28 | 2011-04-07 | Pfizer | Derivados de dioxa-biciclo[3.2.1]octano-2,3,1-triol. |
| TW201038580A (en) | 2009-02-02 | 2010-11-01 | Pfizer | 4-amino-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-6(5H)-yl)phenyl derivatives |
| CA2754685A1 (en) | 2009-03-11 | 2010-09-16 | Pfizer Inc. | Substituted indazole amides |
| JP5086480B2 (ja) | 2009-03-11 | 2012-11-28 | ファイザー・インク | グルコキナーゼ活性化剤として使用されるベンゾフラニル誘導体 |
| US20120095028A1 (en) | 2009-03-20 | 2012-04-19 | Pfizer Inc. | 3-oxa-7-azabicyclo[3.3.1]nonanes |
| TW201038572A (en) * | 2009-03-25 | 2010-11-01 | Gruenenthal Gmbh | Substituted spiro-amide compounds |
| WO2010128414A1 (en) | 2009-05-08 | 2010-11-11 | Pfizer Inc. | Gpr 119 modulators |
| CA2759843A1 (en) | 2009-05-08 | 2010-11-10 | Pfizer Inc. | Gpr 119 modulators |
| US20120083476A1 (en) * | 2009-06-05 | 2012-04-05 | Janssen Pharmaceutica Nv | Heteroaryl-substituted spirocyclic diamine urea modulators of fatty acid amide hydrolase |
| NZ596467A (en) | 2009-06-05 | 2014-01-31 | Pfizer | L- ( piperidin-4-yl) -pyrazole derivatives as gpr 119 modulators |
| WO2011005611A1 (en) | 2009-07-09 | 2011-01-13 | Merck Sharp & Dohme Corp. | Neuromedin u receptor agonists and uses thereof |
-
2011
- 2011-03-11 HU HUE11713083A patent/HUE025774T2/en unknown
- 2011-03-11 RU RU2012137489/04A patent/RU2524341C2/ru not_active IP Right Cessation
- 2011-03-11 DK DK11713083.1T patent/DK2547679T3/en active
- 2011-03-11 HR HRP20151232TT patent/HRP20151232T1/hr unknown
- 2011-03-11 SI SI201130664T patent/SI2547679T1/sl unknown
- 2011-03-11 PH PH1/2012/501800A patent/PH12012501800A1/en unknown
- 2011-03-11 JP JP2013500620A patent/JP5496409B2/ja not_active Expired - Fee Related
- 2011-03-11 CN CN201180014627.7A patent/CN102939290B/zh not_active Expired - Fee Related
- 2011-03-11 PT PT117130831T patent/PT2547679E/pt unknown
- 2011-03-11 AU AU2011228699A patent/AU2011228699B2/en not_active Ceased
- 2011-03-11 RS RS20150808A patent/RS54383B1/sr unknown
- 2011-03-11 WO PCT/IB2011/051035 patent/WO2011114271A1/en not_active Ceased
- 2011-03-11 KR KR1020127027230A patent/KR101455917B1/ko not_active Expired - Fee Related
- 2011-03-11 CA CA2792234A patent/CA2792234C/en not_active Expired - Fee Related
- 2011-03-11 ME MEP-2015-189A patent/ME02330B/me unknown
- 2011-03-11 PL PL11713083T patent/PL2547679T3/pl unknown
- 2011-03-11 MX MX2012010772A patent/MX2012010772A/es active IP Right Grant
- 2011-03-11 BR BR112012023664A patent/BR112012023664B1/pt not_active IP Right Cessation
- 2011-03-11 SG SG2012062667A patent/SG183812A1/en unknown
- 2011-03-11 EP EP11713083.1A patent/EP2547679B1/en active Active
- 2011-03-11 ES ES11713083.1T patent/ES2557895T3/es active Active
- 2011-03-16 TW TW100109022A patent/TWI410423B/zh not_active IP Right Cessation
- 2011-03-16 US US13/049,225 patent/US8609680B2/en active Active
- 2011-03-18 AR ARP110100888A patent/AR080688A1/es not_active Application Discontinuation
-
2012
- 2012-09-13 IL IL221952A patent/IL221952A/en not_active IP Right Cessation
-
2013
- 2013-11-18 US US14/083,275 patent/US20140080756A1/en not_active Abandoned
-
2015
- 2015-12-04 CY CY20151101105T patent/CY1118721T1/el unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1898239A (zh) * | 2003-10-23 | 2007-01-17 | 阿斯利康(瑞典)有限公司 | 新的二氮杂螺烷及其在治疗ccr8介导的疾病中的用途 |
| WO2007007069A1 (en) * | 2005-07-07 | 2007-01-18 | Vernalis (R & D) Limited | Azacyclic compounds as inhibitors of sensory neurone specific sodium channels |
| CN101541795A (zh) * | 2006-09-15 | 2009-09-23 | 先灵公司 | 用于治疗疼痛、糖尿病和脂类代谢紊乱的螺-稠合氮杂环丁烷衍生物 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102939290B (zh) | 2,3-二氢-1h-茚-1-基-2,7-二氮杂螺[3.5]壬烷衍生物及其作为生长激素释放肽受体的拮抗剂或反向激动剂的用途 | |
| CN103189377B (zh) | N1/n2-内酰胺乙酰辅酶a羧化酶抑制剂 | |
| TWI464171B (zh) | 經取代之乙醯輔酶ａ羧化酶抑制劑類 | |
| JP2015515472A (ja) | ジアシルグリセロールアシルトランスフェラーゼ２阻害薬 | |
| WO2021233236A1 (zh) | 取代的杂芳基化合物及其组合物和用途 | |
| CN109928971B (zh) | 芳基取代的氨基四氢吡喃类化合物及其用途 | |
| HK1182094B (en) | 2,3 dihydro-1h-inden-1-yl-2,7-diazaspiro [3.5] nonane derivatives and their use as antagonists or inverse agonists of the ghrelin receptor | |
| JP7573009B2 (ja) | メラノコルチン４受容体アンタゴニストとしてのスピロ化合物およびそれらの使用 | |
| US20240238425A1 (en) | HSD17B13 Inhibitors and/or Degraders | |
| JP2025541231A (ja) | ３－フルオロ－４－ヒドロキシベンズアミド含有阻害剤および／または分解剤ならびにそれらの使用 | |
| HK1229322A1 (en) | Pyrazolospiroketone derivatives for ues as acetyl-coa carboxylase inhibitors | |
| HK1190154A (en) | Pyrazolospiroketone derivatives for ues as acetyl-coa carboxylase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1182094 Country of ref document: HK |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1182094 Country of ref document: HK |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150916 Termination date: 20210311 |